-
March 2026: This Month in Huntington’s Disease Research
Latest News
-
Welcome to HDBuzz
Welcome to HDBuzz. Huntington’s disease research news. In plain language. Written by scientists. For the global HD co
-
Memantine in HD: dose is everything
Memantine, a drug already used in Alzheimer’s disease, might help in HD, but a mouse study shows dose is everything.
-
An active lifestyle may make a difference to HD symptoms
More reasons to be active: a passive lifestyle may contribute to earlier onset of symptoms in HD.
-
Frequently asked questions, January 2011
Answers to frequently-asked questions about HD – the first in a regular series of HDBuzz FAQ articles.
-
Getting the data out – a new scientific journal just for HD
New scientific journal PLoS Currents HD promises rapid publication & open access, improving scientific communication
-
Dimebon: disappointing in Alzheimer’s but might work in HD
Dimebon – disappointing results in an Alzheimer’s disease trial, but hope remains for HD.
-
Does HD cause brains to develop differently?
Smaller total brain volumes in male HD mutation carriers suggests brain development may be different in HD.
-
Is Huntington’s disease twice as common as we thought?
New data suggest there may be twice as many people with HD symptoms as previously thought – and even more at risk
-
Two large HD observational studies – COHORT and Registry – merge to create ENROLL-HD
Merger of two major Huntington’s Disease observational trials creates ENROLL-HD
-
Huntexil for symptoms of Huntington's disease: where are we now?
Two clinical trials in Europe and the USA have suggested a new drug, Huntexil, might improve movements in HD. The nex
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
